作者
Chad A Bousman, Susanne A Bengesser, Katherine J Aitchison, Azmeraw T Amare, Harald Aschauer, Bernhard T Baune, Bahareh Behroozi Asl, Jeffrey R Bishop, Margit Burmeister, Boris Chaumette, Li-Shiun Chen, Zachary A Cordner, Jürgen Deckert, Franziska Degenhardt, Lynn E DeLisi, Lasse Folkersen, James L Kennedy, Teri E Klein, Joseph L McClay, Francis J McMahon, Richard Musil, Nancy L Saccone, Katrin Sangkuhl, Robert M Stowe, Ene-Choo Tan, Arun K Tiwari, Clement C Zai, Gwyneth Zai, Jianping Zhang, Andrea Gaedigk, Daniel J Müller
发表日期
2021/1
来源
Pharmacopsychiatry
卷号
54
期号
01
页码范围
5-17
出版商
Georg Thieme Verlag KG
简介
The implementation of pharmacogenomic (PGx) testing in psychiatry remains modest, in part due to divergent perceptions of the quality and completeness of the evidence base and diverse perspectives on the clinical utility of PGx testing among psychiatrists and other healthcare providers. Recognizing the current lack of consensus within the field, the International Society of Psychiatric Genetics assembled a group of experts to conduct a narrative synthesis of the PGx literature, prescribing guidelines, and product labels related to psychotropic medications as well as the key considerations and limitations related to the use of PGx testing in psychiatry. The group concluded that to inform medication selection and dosing of several commonly-used antidepressant and antipsychotic medications, current …
学术搜索中的文章
CA Bousman, SA Bengesser, KJ Aitchison, AT Amare… - Pharmacopsychiatry, 2021